nabiximols + omeprazole

**nabiximols + omeprazole** is a combination of two pharmaceutical drugs: - **Nabiximols (Sativex)** is an oromucosal spray containing a standardized 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), both derived from Cannabis sativa. It acts as a partial agonist at cannabinoid receptors and modulates the balance between excitatory and inhibitory neurotransmitters in the central nervous system. Nabiximols is primarily indicated for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medications[3][5][7][8]. It may also be used adjunctively for neuropathic pain in MS and cancer-related pain. - **Omeprazole** is a small molecule proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system on gastric parietal cells. This action suppresses gastric acid secretion by blocking the final step of acid production. Omeprazole is indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, erosive esophagitis, and Helicobacter pylori eradication[1][2][4][6]. There are no known fixed-dose combinations of these two agents; this entry describes their concurrent use rather than a co-formulated product.

Brand names

PriLOSECPriLOSEC OTCZegeridFIRST Omeprazole

Other names

Sativex oromucosal spray